Immunotherapy & Immunophenotyping for Sepsis Treatment

Therapeutic to boost patients’ immune response using Interleukin-15 (IL-15) to stimulate T cell production to combat the underlying cause of sepsis

- Prolonged treatment at reduced IL-15 quantities >> boosts immune response + reduces side effects and toxicities
- Therapeutic + diagnostic + prognostic system to treat and manage patients
- Real-time status updates to monitor therapeutic interventions
- Requires very small blood volumes for safe use with neonates and infants
- Single application, pharmaceutical-grade injectable delivered bedside

Potential Partners
- PerkinElmer
- Vedantra Pharmaceuticals

Investigational New Drug (IND) regulatory pathway

License Technology/Therapy

PROJECT MILESTONES

MONTH 1
- Produce nanoparticles and conduct dose response study

MONTH 2
- Conduct delayed treatment study and data analysis for biomarkers

MONTH 3

MONTH 4

MONTH 5

MONTH 6